CoChat
Sign Up
Cited by 1

Modulating ApoE with Tissue Specific siRNAs in Alzheimer’s Disease

Ferguson, Chantal·2021·University of Massachusetts Medical School
DOI 10.13028/qk23-zg81
Open this paper in CoChat — free account

Abstract

Among many putative genetic risk variations reported to date, the ApoE4 allele remains the most common genetic risk factor for late-onset AD, and is associated with both an increase in incidence and a decrease in age of clinical onset. The majority of ApoE is produced in the: 1) central nervous system (CNS) by astrocytes to transport lipids between cells and modulate the inflammatory response; and 2) liver, where it facilitates lipid uptake into peripheral tissues via low-density lipoprotein (LDL) receptors. Consistent with its dual roles, genetic knockout of ApoE increases the risk for atherosclerosis, but it also dramatically improves AD phenotypes in mouse models. Antisense oligonucleotide (ASO) based modulation of CNS ApoE has only marginal effects on AD phenotypes, suggesting that post-embryonic silencing of ApoE is not a viable therapeutic strategy. However, the recent development of novel CNS siRNA chemical structures enables widespread distribution and potent target silencing throughout the brain. Using this technology, we demonstrate that liver and brain ApoE pools are spatially and functionally distinct, and that complete silencing of brain, not liver, ApoE results in robust reduction of amyloid plaque formation, without impacting systemic cholesterol. Furthermore, RNAseq analysis shows minimal off target effects of the siRNAs and identifies immune modulation and metabolic alterations as potential mechanisms behind ApoE’s role in plaque formation and clearance. Moving forward, these results build upon the rationale to modulate ApoE expression and provide the technology necessary to further evaluate the impact ApoE silencing in AD and other neurodegenerative diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

DataCite · 10.13028/qk23-zg81

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tissue-specific apoE siRNAs completely silenced apoE expression in the brain, had no effects on systemic cholesterol and greatly inhibited amyloid plaque formation in APP/PS1 transgenic mice.

    “tissue-specific apoE siRNAs completely silenced apoE expression in the brain, had no effects on systemic cholesterol and greatly inhibited amyloid plaque formation in APP/PS1 transgenic mice”

    From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Ferguson 2021

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 245

  1. Julia F. Alterman#, Bruno M.D.C. Godinho#, Matthew R. Hassler#, Chantal M Ferguson#, Dimas Echeverria, Ellen Sapp, Reka A. Haraszti, Andrew H. Coles, Faith Conroy, Rachael Miller, Loic Roux, Robert M. King, Gwladys Gernoux, Christian Mueller, Heather L. Gray-Edwards, Richard P. Moser, Nina C. Bishop, Samer M. Jaber, Matthew J. Gounis, Miguel Sena Esteves, Marian DiFiglia, Neil Aronin, Anastasia Khvorova. A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nature biotechnology 37, 884-894, doi:10.1038/s41587-019-0205-0 (2019). #These authors contributed equally. The following publications are contributing author works that are not included in the dissertation: · DOI · Paper page
  2. Didiot, M.C., Ferguson, C.M., Ly, S., Coles, A.H., Smith, A.O., Bicknell, A.A., Hall, L.M., Sapp, E., Echeverria, D., Pai, A.A., et al. (2018). Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin. Cell reports 24, 2553- 2560.e2555. Manuscripts in process:
  3. Socheata Ly 1 *, Marie-Cécile Didiot 1 *, Chantal M. Ferguson 1 *, Andrew H. Coles 1 , Rachael Miller 1 , Kathryn Chase 1 , Dimas Echeverria 1 , Feng Wang 1 , Neil Aronin 1,2 , Anastasia Khvorova 1,3,4 *. Mutant Huntingtin mRNA Forms Nuclear Clusters that are Resistant to Oligonucleotide-based Silencing In Vivo. Under Review with Cell Reports.
  4. Ferguson, Chantal. 2020. Oligonucleotides for SYNGR3 Modulation. March 10, 2021. Application in Process Bibliography
  5. Akinc, A., et al. 2010 Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18(7):1357-64.
  6. Alterman, J. F., et al. 2019 A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system. Nat Biotechnol 37(8):884-894.
  7. Amir Qaseem, Vincenza Snow, J. Thomas Cross Jr., Mary Ann Forciea, Robert Hopkins Jr., Paul Shekelle, Alan Adelman, David Mehr, Kenneth Schellhase, Doug Campos- Outcalt, Pasqualina Santaguida, Douglas K. Owens, and the Joint American College of Physicians/American Academy of Family Physicians Panel on Dementia 2008 Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. Annals of Internal Medicine 148(5):370-378.
  8. Anne M. Fagan, Guojon Bu, Yuling Sun, Alan Daugherty, David M. Holtzman 1996 Apolipoprotein E-containing High Density Lipoprotein Promotes Neurite Outgrowth and Is a Ligand for the Low Density Lipoprotein Receptor-related Protein. The Journal of Biological Chemistry 271(47):30121-20125.
  9. Arboleda-Velasquez, J. F., et al. 2019 Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med 25(11):1680-1683.
  10. Arnsten, Amy F. T., et al. 2021 Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease. Alzheimer's & Dementia 17(1):115-124.
  11. Atwood, Craig S., et al. 2002 Senile plaque composition and posttranslational modification of amyloid-β peptide and associated proteins. Peptides 23(7):1343-1350.
  12. Bales, K. R., et al. 2009 Human APOE Isoform-Dependent Effects on Brain -Amyloid Levels in PDAPP Transgenic Mice. Journal of Neuroscience 29(21):6771-6779.
  13. Bales, Kelly R., et al. 1997 Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nature Genetics 17(3):263-264.
  14. Basak, J. M., et al. 2012 Low-density lipoprotein receptor represents an apolipoprotein E- independent pathway of Abeta uptake and degradation by astrocytes. J Biol Chem 287(17):13959-71.
  15. Beffert, Uwe, et al. 1999 Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Research 843(1-2):87-94.
  16. Belinson, H., et al. 2010 Following activation of the amyloid cascade, apolipoprotein E4 drives the in vivo oligomerization of amyloid-beta resulting in neurodegeneration. J Alzheimers Dis 22(3):959-70.
  17. Bell, R. D., et al. 2012 Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485(7399):512-6.
  18. Bennett, Rachel E. , et al. 2013 Human Apolipoprotein E4 Worsens Acute Axonal Pathology but Not Amyloid-A Immunoreactivity After Traumatic Brain Injury in 3xTG-AD Mice. J Neuropathol Exp Neurol 72(5):396-403.
  19. Birmingham, A., et al. 2006 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3(3):199-204.
  20. Birmingham, A., et al. 2007 A protocol for designing siRNAs with high functionality and specificity. Nat Protoc 2(9):2068-78.
  21. Bitan, G., et al. 2003 Amyloid -protein (A ) assembly: A 40 and A 42 oligomerize through distinct pathways. Proceedings of the National Academy of Sciences 100(1):330- 335.
  22. Boehm-Cagan, A., et al. 2016 ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies. J Alzheimers Dis 54(3):1219-1233.
  23. Boehm-Cagan, A., and D. M. Michaelson 2014 Reversal of apoE4-Driven Brain Pathology and Behavioral Deficits by Bexarotene. Journal of Neuroscience 34(21):7293-7301.
  24. Bolger, A. M., M. Lohse, and B. Usadel 2014 Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30(15):2114-20.
  25. Boyles, J. K., et al. 1985 Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. Journal of Clinical Investigation 76(4):1501-1513.
  26. Breen, K. C., M. Bruce, and B. H. Anderton 1991 Beta amyloid precursor protein mediates neuronal cell-cell and cell- surface adhesion. Journal of Neuroscience Research 28(1):90-100.
  27. Bruce A. Yankner, Lawrence K. Duffy, Daniel A. Kirschner 1990 Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250(4978):279-282.
  28. Bu, Guojun 2009 Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nature Reviews Neuroscience 10(5):333-344.
  29. Burchard, J., et al. 2009 MicroRNA-like off-target transcript regulation by siRNAs is species specific. RNA 15(2):308-15.
  30. Burdick, D., et al. 1992 Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. Journal of Biological Chemistry 267(1):546-554.
  31. Castellano, J. M., et al. 2011 Human apoE Isoforms Differentially Regulate Brain Amyloid-Peptide Clearance. Science Translational Medicine 3(89):89ra57-89ra57.
  32. Champagne, D., et al. 2003 The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience 121(1):99-110.
  33. Chen, Hung-Kai, et al. 2012 Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons. Journal of Biological Chemistry 287(8):5253-5266.
  34. Coles, A. H., et al. 2016 A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo. Nucleic Acid Ther 26(2):86-92.
  35. Cramer, P. E., et al. 2012 ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models. Science 335(6075):1503-1506.
  36. Cummings, J., et al. 2020 Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement (N Y) 6(1):e12050.
  37. Da Mesquita, Sandro, et al. 2018 Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease. Nature 560(7717):185-191.
  38. Dahlgren, Karie N., et al. 2002 Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability. Journal of Biological Chemistry 277(35):32046-32053.
  39. Daniel Press, MD, Michael Alexander, MD 2021a Cholinesterase inhibitors in the treatment of Alzheimer disease. UpToDate. - 2021b Management of neuropsychiatric symptoms of dementia. UpToDate.
  40. David M. Holtzman, Kelly R. Bales, Shan Wu, Priyanka Bhat, Maia Parsadanian, Anne M. Fagan, Louis K. Chang, Yuling Sun, and Steven M. Paul 1999 Expression of human apolipoprotein E reduces amyloid-β deposition in a mouse model of Alzheimer's disease. Journal of Clinical Investigation 103(6):15- 21.
  41. David M. Holtzman, Kelly R. Bales, Tanya Tenkova , Anne M. Fagan, Maia Parsadanian, Leah J. Sartorius, Brian Mackey, John Olney, Daniel McKeel, David Wozniak, and Steven M. Paul 2000 Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. PNAS 97(6):2892-2897.
  42. De Strooper, B., and E. Karran 2016 The Cellular Phase of Alzheimer's Disease. Cell 164(4):603-15.
  43. De Strooper, Bart, et al. 1998 Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391(6665):387-390.
  44. Deane, Rashid, et al. 2008 apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. Journal of Clinical Investigation 118(12):4002-4013.
  45. Devi, Latha, and Masuo Ohno 2012 Mitochondrial dysfunction and accumulation of the β-secretase-cleaved C-terminal fragment of APP in Alzheimer's disease transgenic mice. Neurobiology of Disease 45(1):417-424.
  46. Didiot, Marie-Cécile, et al. 2018 Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin. Cell Reports 24(10):2553-2560.
  47. Dobin, A., et al. 2013 STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15-21.
  48. Dodart, J. C., et al. 2005 Gene delivery of human apolipoprotein E alters brain A burden in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences 102(4):1211-1216.
  49. E. H. Corder, A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, A. D. Roses, J. L. Haines, M. A. Pericak-Vance 1993 Gene Dose of Apolipoprotein E Type 4 Allele and the Risk fo Alzheimer's Disease in Late Onset Families. Science 261:921-923.
  50. Egan, M. F., et al. 2018 Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med 378(18):1691-1703.
  51. Elize D. Haasdijk, Angela Vlug, Monique T. Mulder, Dick Jaarsma 2002 Increased apolipoprotein E expression correlates with the onset of neuronal degeneration in the spinal cord of G93A-SOD1 mice. Neuroscience Letters 335:29-33.
  52. Eulalio, A., et al. 2007 P-body formation is a consequence, not the cause, of RNA-mediated gene silencing. Mol Cell Biol 27(11):3970-81.
  53. Fagan, A. M., et al. 2002 Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 9(3):305-18.
  54. Fagan, Anne M., et al. 1999 Unique Lipoproteins Secreted by Primary Astrocytes From Wild Type, apoE (-/-), and Human apoE Transgenic Mice. Journal of Biological Chemistry 274(42):30001-30007.
  55. Fakhr, E., F. Zare, and L. Teimoori-Toolabi 2016 Precise and efficient siRNA design: a key point in competent gene silencing. Cancer Gene Ther 23(4):73-82.
  56. Farrell, M. E., et al. 2017 Association of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults: Evidence for a Dose-Response Relationship. JAMA Neurol 74(7):830-838.
  57. Farrer, Lindsay PhD; L. Adrienne Cupples, PhD; Jonathan L. Haines, PhD; Bradley Hyman, MD, PhD; Walter A. Kukull, PhD; Richard Mayeux, MD; Richard H. Myers, PhD; Margaret A. Pericak-Vance, PhD;, and PhD; Cornelia M. van Duijn Neil Risch, PhD; for the APOE and Alzheimer Disease Meta Analysis Consortium 1997 Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease. JAMA 278(16):1349-1356.
  58. Fire, Andrew, et al. 1998 Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391(6669):806-811.
  59. Fitz, N. F., et al. 2020 Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice. Mol Neurodegener 15(1):41.
  60. Frautschy, S. A., et al. 1998 Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol 152(1):307-17.
  61. Fu, Y., et al. 2016 Apolipoprotein E lipoprotein particles inhibit amyloid-beta uptake through cell surface heparan sulphate proteoglycan. Mol Neurodegener 11(1):37.
  62. Gagnon, K. T., et al. 2014a RNAi factors are present and active in human cell nuclei. Cell Rep 6(1):211-21.
  63. Gagnon, K. T., et al. 2014b Analysis of nuclear RNA interference in human cells by subcellular fractionation and Argonaute loading. Nat Protoc 9(9):2045-60.
  64. Garcia-Alloza, M., et al. 2006 Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24(3):516-24.
  65. Goedert, Michel, and Maria Grazia Spillantini 2000 Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. Biochimica et Biophysica Acta (BBA) -Molecular Basis of Disease 1502(1):110-121.
  66. Growdon, Whitfield B., et al. 1999 Lack of allelic imbalance in APOE ϵ 3/4 brain mRNA expression in Alzheimer's disease. Neuroscience Letters 272(2):83-86.
  67. Gu, L., and Z. Guo 2013 Alzheimer's Abeta42 and Abeta40 peptides form interlaced amyloid fibrils. J Neurochem 126(3):305-11.
  68. Guptill, Jeffrey T., et al. 2017 Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects. The Journal of Clinical Pharmacology 57(6):770-776.
  69. Han, A., et al. 2014 De novo prediction of PTBP1 binding and splicing targets reveals unexpected features of its RNA recognition and function. PLoS Comput Biol 10(1):e1003442.
  70. Hanson, Angela J., et al. 2013 Effect of Apolipoprotein E Genotype and Diet on Apolipoprotein E Lipidation and Amyloid Peptides. JAMA Neurology 70(8):972.
  71. Haraszti, R. A., et al. 2017 5-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids Res 45(13):7581-7592.
  72. Harmon, Steven W. Barger and Ashley D. 1997 Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Letters to Nature 388:878-881.
  73. Hassler, M. R., et al. 2018 Comparison of partially and fully chemically-modified siRNA in conjugate- mediated delivery in vivo. Nucleic Acids Res 46(5):2185-2196.
  74. He, X., et al. 2007 Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E- induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production. J Neurosci 27(15):4052-60.
  75. Hetz, C., and B. Mollereau 2014 Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases. Nat Rev Neurosci 15(4):233-49.
  76. Hickman, Suzanne E., et al. 2013 The microglial sensome revealed by direct RNA sequencing. Nature Neuroscience 16(12):1896-1905.
  77. Hippius, Hanns, and Gabriele Neundorfer 2003 The discovery of Alzheimer's disease. Dialogues in Clinical Neuroscience 5(1):101-108.
  78. Hirsch-Reinshagen, V., et al. 2004 Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 279(39):41197-207.
  79. Holtzman, D. M., J. Herz, and G. Bu 2012 Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2(3):a006312.
  80. Honig, Lawrence S., et al. 2018 Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. New England Journal of Medicine 378(4):321-330.
  81. Hu, Jin, et al. 2015 Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice. Molecular Neurodegeneration 10(1):6.
  82. Huang, Y. A., et al. 2017 ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Abeta Secretion. Cell 168(3):427-441 e21.
  83. Huang, Y., et al. 2001 Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proceedings of the National Academy of Sciences 98(15):8838-8843.
  84. Hudry, E., et al. 2013 Gene Transfer of Human Apoe Isoforms Results in Differential Modulation of Amyloid Deposition and Neurotoxicity in Mouse Brain. Science Translational Medicine 5(212):212ra161-212ra1.
  85. Hui Zheng, MinghaoJ iang, Myrna E.Trumbauer, Dalip J.S.Sirinathsinghji, RuthHopkins, David W.Smith, Robert P.Heavens, Gerard R.Dawson, SusanBoyce, Michael W.Conner, Karla A.Stevens, Hilda H.Slunt, Sangram S.Sisodia, Howard Y.Chen, Lex H.T.Van der Ploeg 1995 β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell Press 81(4):525-531.
  86. Hunter, J. D. 2007 Matplotlib: A 2D Graphics Environment. Computing in Science & Engineering 9(3):90-95.
  87. Huppi, K., S. E. Martin, and N. J. Caplen 2005 Defining and assaying RNAi in mammalian cells. Mol Cell 17(1):1-10.
  88. Huynh, T. V., et al. 2017 Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of beta-amyloidosis. Neuron 96(5):1013-1023 e4.
  89. Huynh, T. V., et al. 2019 Lack of hepatic apoE does not influence early Abeta deposition: observations from a new APOE knock-in model. Mol Neurodegener 14(1):37.
  90. Hyman, B. T., et al. 1984 Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225(4667):1168-70.
  91. Hyman, Bradley T., and John Q. Trojanowski 1997 Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology 56(10):1095-1097.
  92. Ikonomovic, Milos D., et al. 2006 X-34 Labeling of Abnormal Protein Aggregates During the Progression of Alzheimer's Disease. In Amyloid, Prions, and Other Protein Aggregates, Part B. Pp. 123-144. Methods in Enzymology.
  93. Iliff, J. J., et al. 2012 A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci Transl Med 4(147):147ra111.
  94. Irit Gordon, Ettie Grauer, Idit Genis, Ephraim Sehayek, Daniel M. Michaelsona 1995 Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neuroscience Letters 199:1-4.
  95. Jack, Clifford R., M.D., Ronald C. Petersen, Ph.D.,M.D., Yue Cheng Xu, M.D., Ph.D, Stephen C. Waring, D.V.M., Ph.D., Peter C. O'Brien, Ph.D., Eric G. Tangalos, M.D., Glenn E. Smith, Ph.D., Robert J. Ivnik, Ph.D., and Emre Kokmen, Ms.D. 1997 Medial Temporal Atrophy on MRI in Normal Aging and Very Mild Alzheimer's Disease. Neurology 49(3):786-794.
  96. Jackson, A. L., et al. 2006 Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12(7):1179-87.
  97. Jackson, A. L., and P. S. Linsley 2010 Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 9(1):57-67.
  98. Janas, M. M., et al. 2018 Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun 9(1):723.
  99. Jankowsky, J. L., et al. 2004 Mutant presenilins specifically elevate the levels of the 42 residue beta- amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13(2):159-70.
  100. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. 2001 Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Engineering 16(6):157-65.
  101. Janus, C., et al. 2015 Behavioral abnormalities in APPSwe/PS1dE9 mouse model of AD-like pathology: comparative analysis across multiple behavioral domains. Neurobiol Aging 36(9):2519-32.
  102. Jarrett, Joseph T., Elizabeth P. Berger, and Peter T. Lansbury 1993 The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 32(18):4693-4697.
  103. Jones, Phillip B., et al. 2011 Apolipoprotein E: Isoform Specific Differences in Tertiary Structure and Interaction with Amyloid-β in Human Alzheimer Brain. PLoS ONE 6(1):e14586.
  104. Jui-Cheng, Yen, Chang Fu-Juay, and Chang Shyang 1995 A new criterion for automatic multilevel thresholding. IEEE Transactions on Image Processing 4(3):370-378.
  105. Kadavath, H., et al. 2015 Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc Natl Acad Sci U S A 112(24):7501-6.
  106. Kalantari, R., C. M. Chiang, and D. R. Corey 2016a Regulation of mammalian transcription and splicing by Nuclear RNAi. Nucleic Acids Res 44(2):524-37.
  107. Kalantari, R., et al. 2016b Stable association of RNAi machinery is conserved between the cytoplasm and nucleus of human cells. RNA 22(7):1085-98.
  108. Kanekiyo, T., et al. 2011 Heparan Sulphate Proteoglycan and the Low-Density Lipoprotein Receptor-Related Protein 1 Constitute Major Pathways for Neuronal Amyloid-Uptake. Journal of Neuroscience 31(5):1644-1651.
  109. Kang, Jie, et al. 1987 The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325(6106):733-736.
  110. Khvorova, A., and J. K. Watts 2017 The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol 35(3):238-248.
  111. Kim, J., et al. 2011 Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci 31(49):18007-12.
  112. Kim, Jungsu, Jacob M. Basak, and David M. Holtzman 2009 The Role of Apolipoprotein E in Alzheimer's Disease. Neuron 63(3):287- 303.
  113. Klein, R. C., et al. 2010 Progressive loss of synaptic integrity in human apolipoprotein E4 targeted replacement mice and attenuation by apolipoprotein E2. Neuroscience 171(4):1265-1272.
  114. Koistinaho, Milla, et al. 2004 Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nature Medicine 10(7):719-726.
  115. Koopal, C., A. D. Marais, and F. L. Visseren 2017 Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. Curr Opin Endocrinol Diabetes Obes 24(2):133-139.
  116. Kowal, R. C., et al. 1990 Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. Journal of Biological Chemistry 265(18):10771-10779.
  117. Krasemann, S., et al. 2017 The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity 47(3):566-581
  118. Krstic, D., and I. Knuesel 2013 Deciphering the mechanism underlying late-onset Alzheimer disease. Nat Rev Neurol 9(1):25-34.
  119. Kucukural, A., et al. 2019 DEBrowser: interactive differential expression analysis and visualization tool for count data. BMC Genomics 20(1):6.
  120. Labbadia, Johnathan, and Richard I. Morimoto 2015 The Biology of Proteostasis in Aging and Disease. Annual Review of Biochemistry 84(1):435-464.
  121. Ladu, M. J., et al. 1994 Isoform-specific binding of apolipoprotein E to beta-amyloid. Journal of Biological Chemistry 269(38):23403-23406.
  122. LaDu, M. J., et al. 2000 Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures. J Biol Chem 275(43):33974-80.
  123. Lambert, J. C., et al. 1997 Distortion of Allelic Expression of Apolipoprotein E in Alzheimer's Disease. Human Molecular Genetics 6(12):2151-2154.
  124. Lane, E. M., et al. 2017 Insulin-like growth factor binding protein-2 interactions with Alzheimer's disease biomarkers. Brain Imaging Behav 11(6):1779-1786.
  125. Lane-Donovan, C., et al. 2016 Genetic Restoration of Plasma ApoE Improves Cognition and Partially Restores Synaptic Defects in ApoE-Deficient Mice. J Neurosci 36(39):10141-50.
  126. Langmead, B., and S. L. Salzberg 2012 Fast gapped-read alignment with Bowtie 2. Nat Methods 9(4):357-9.
  127. Lennox, K. A., and M. A. Behlke 2016 Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acids Res 44(2):863-77.
  128. Li, Y. J., et al. 2004 Apolipoprotein E is associated with age at onset of amyotrophic lateral sclerosis. Neurogenetics 5(4):209-13.
  129. Liao, F., et al. 2014 Anti-ApoE Antibody Given after Plaque Onset Decreases A Accumulation and Improves Brain Function in a Mouse Model of A Amyloidosis. Journal of Neuroscience 34(21):7281-7292.
  130. Liao, Fan, et al. 2018 Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. Journal of Clinical Investigation 128(5):2144-2155.
  131. Liddelow, Shane A., et al. 2017 Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541(7638):481-487.
  132. Lin, Y. T., et al. 2018 APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types. Neuron 98(6):1141-1154 e7.
  133. Ling Guo, Mary Jo LaDu, and Linda J. Van Eldik 2004 A Dual Role for Apolipoprotein E in Neuroinflammation. Journal of Molecular Neuroscience 23:205-212.
  134. Litvinchuk, Alexandra, et al. 2021 Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model. Annals of Neurology.
  135. Liu, C. C., et al. 2013a Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106-18.
  136. Liu, C. C., et al. 2017a ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron 96(5):1024-1032 e3.
  137. Liu, C. C., et al. 2016 Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer's disease. Sci Transl Med 8(332):332ra44.
  138. Liu, C., et al. 2012 Effects of a novel pharmacologic inhibitor of myeloperoxidase in a mouse atherosclerosis model. PLoS One 7(12):e50767.
  139. Liu, P., et al. 2017b Quantitative Comparison of Dense-Core Amyloid Plaque Accumulation in Amyloid-beta Protein Precursor Transgenic Mice. J Alzheimers Dis 56(2):743- 761.
  140. Liu, S. Y., et al. 2013b Polymorphism -116C/G of human X-box-binding protein 1 promoter is associated with risk of Alzheimer's disease. CNS Neurosci Ther 19(4):229-34.
  141. Liu, Y., et al. 2018 Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression. Sci Rep 8(1):14600.
  142. Ljungberg, M. C., et al. 2003 Apolipoprotein E (apoE) uptake and distribution in mammalian cell lines is dependent upon source of apoE and can be monitored in living cells. Neuroscience Letters 341(1):69-73.
  143. Love, M. I., W. Huber, and S. Anders 2014 Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550.
  144. Ly, S., et al. 2017 Visualization of self-delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Res 45(1):15-25.
  145. M. X. Tang, G. Maestre, W. Y. Tsai, X. H. Liu, L. Feng, W. Y. Chung, M. Chun, P. Schofield, Y. Stern, B. Tycko, R. Mayeux 1996 Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet. 58(3):574-584.
  146. MacRae F. Linton, Robert Gish, Susan T. Hubi, Esther Butler, Carlos Esquivel, William I. Bry, Janet K. Boyles, Mark R. Wardell, Stephen G. Young 1991 Phenotypes of Apolipoprotein B and Apolipoprotein E after Liver Transplantation. Journal of Clinical Investigation 88:270-281.
  147. Mahley, Robert, and Yadong Huang 2012 Apolipoprotein E Sets the Stage: Response to Injury Triggers Neuropathology. Neuron 76(5):871-885.
  148. Mahley, Robert W., Yadong Huang, and Stanley C. Rall 1999 Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes. Journal of Lipid Research 40(11):1933- 1949.
  149. Mak, A. C., et al. 2014 Effects of the absence of apolipoprotein e on lipoproteins, neurocognitive function, and retinal function. JAMA Neurol 71(10):1228-36.
  150. Mann, K. M., et al. 2004 Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. Hum Mol Genet 13(17):1959-68.
  151. Manocha, G. D., et al. 2016 APP Regulates Microglial Phenotype in a Mouse Model of Alzheimer's Disease. J Neurosci 36(32):8471-86.
  152. Mariot, V., et al. 2017 Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun 8(1):1859.
  153. Martinez, G., et al. 2016 Regulation of Memory Formation by the Transcription Factor XBP1. Cell Rep 14(6):1382-1394.
  154. Matranga, C., et al. 2005 Passenger-strand cleavage facilitates assembly of siRNA into Ago2- containing RNAi enzyme complexes. Cell 123(4):607-20.
  155. Mauger, O., F. Lemoine, and P. Scheiffele 2016 Targeted Intron Retention and Excision for Rapid Gene Regulation in Response to Neuronal Activity. Neuron 92(6):1266-1278.
  156. McIntosh, Annick M., et al. 2012 The Apolipoprotein E (APOE) Gene Appears Functionally Monomorphic in Chimpanzees (Pan troglodytes). PLoS ONE 7(10):e47760.
  157. Minkeviciene, R., et al. 2009 Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci 29(11):3453-62.
  158. Movsesyan, N., et al. 2008 Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine -a novel immunotherapeutic strategy. PLoS One 3(5):e2124.
  159. Muller, U. C., T. Deller, and M. Korte 2017 Not just amyloid: physiological functions of the amyloid precursor protein family. Nat Rev Neurosci 18(5):281-298.
  160. Nair, J. K., et al. 2017 Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res 45(19):10969-10977.
  161. Nair, J. K., et al. 2014 Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc 136(49):16958-61.
  162. Neuner, Sarah M., et al. 2019 Harnessing Genetic Complexity to Enhance Translatability of Alzheimer's Disease Mouse Models: A Path toward Precision Medicine. Neuron 101(3):399- 411.
  163. Nhi-Ha Trinh, Subhanjoy Mohanty Jennifer Hoblyn, and Kristine Yaffe 2003 Efficacy of Cholinesterase Inhibitors in the Treatment of Neuropsychiatric Symptoms and Functional Impairment in Alzheimer Disease. JAMA 289(2):210- 216.
  164. Nixon, R. A. 2017 Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease. FASEB J 31(7):2729-2743.
  165. Oakley, H., et al. 2006 Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40):10129-40.
  166. Oddo, S., et al. 2009 Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. Brain Pathol 19(3):421-30.
  167. Oddo, Salvatore, et al. 2003 Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles. Neuron 39(3):409-421.
  168. Ohno, Masuo, et al. 2006 Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. European Journal of Neuroscience 23(1):251-260.
  169. Olkhanud, P. B., et al. 2012 DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid beta-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease. Vaccine 30(9):1650-8.
  170. Ophir, Gal, et al. 2003 Human apoE3 but not apoE4 rescues impaired astrocyte activation in apoE null mice. Neurobiology of Disease 12(1):56-64.
  171. Ordonez-Gutierrez, L., et al. 2016 AbetaPP/PS1 Transgenic Mice Show Sex Differences in the Cerebellum Associated with Aging. J Alzheimers Dis 54(2):645-56.
  172. Oremus, Parminder Raina; Pasqualina Santaguida; Afisi Ismaila; Christopher Patterson; David Cowan; Mitchell Levine; Lynda Booker; and Mark 2008 Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline. Annals of Internal Medicine 148(5):379-397.
  173. Panza, F., et al. 2019 A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease. Nat Rev Neurol 15(2):73-88.
  174. Parhizkar, Samira, et al. 2019 Loss of TREM2 function increases amyloid seeding but reduces plaque- associated ApoE. Nature Neuroscience 22(2):191-204.
  175. Poduri, Annapurna, et al. 1994 Apolipoprotein E4 and Beta Amyloid in Senile Plaques and Cerebral Blood Vessels of Aged Rhesus Monkeys. American Journal of Pathology 144(6).
  176. Poirier, Judes, et al. 1991 Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Molecular Brain Research 11(2):97-106.
  177. Poirier, Uwe Beffert and Judes 1998 ApoE associated with lipid has a reduced capacity to inhibit ß-amyloid fibril formation. NeuroReport 9(14):3321-3323.
  178. Polymenidou, M., et al. 2011 Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14(4):459-68.
  179. Post, N., et al. 2019 Metabolism and Disposition of Volanesorsen, a 2'-O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos 47(10):1164- 1173.
  180. Praline, J., et al. 2011 APOE epsilon4 allele is associated with an increased risk of bulbar-onset amyotrophic lateral sclerosis in men. Eur J Neurol 18(8):1046-52.
  181. Qiao, Xiaoxi, David J. Cummins, and Steven M. Paul 2001 Neuroinflammation-induced acceleration of amyloid deposition in the APPV717Ftransgenic mouse. European Journal of Neuroscience 14(3):474-482.
  182. Qin Xu, Aubrey Bernardo, David Walker, Tifany Kanegawa, Robert W. Mahley, and Yadong Huang 2006 Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Flourescent Protein Gene to teh ApoE Locus. Neurobiology of Disease 26(19):4985-4994.
  183. R. Anderson, J.C. Barnes, T. V. P. Bliss, D.P. Cain, K. Cambon, H. A. Davies, M.L. Errington, L.A. Fellows R. A. Gray, T. HOh, M. Stweart, C. H. Large, G. A. Higgins 1998 Behavioural, Physiological, and Morphological Analysis of A Line of Apoliporotein E Knockout Mouse. Neuroscience 85(1):93-110.
  184. Raber, Jacob, Yadong Huang, and J. Wesson Ashford 2004 ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiology of Aging 25(5):641-650.
  185. Rangaraju, S., et al. 2018 Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer's disease. Mol Neurodegener 13(1):24.
  186. Ray, K. K., et al. 2020 Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med 382(16):1507-1519.
  187. Reiman, E. M., et al. 2020 Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a 5,000-person neuropathological study. Nat Commun 11(1):667.
  188. Reiman, E. M., et al. 2009 Fibrillar amyloid-burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proceedings of the National Academy of Sciences 106(16):6820-6825.
  189. Reitz, C., and R. Mayeux 2014 Genetics of Alzheimer's disease in Caribbean Hispanic and African American populations. Biol Psychiatry 75(7):534-41.
  190. Reynolds, A., et al. 2004 Rational siRNA design for RNA interference. Nat Biotechnol 22(3):326- 30.
  191. Robert E. Pitas, Janet K. Boyles, Susan H. Lees, DavidHui, and Karl H. Weisgraber 1987 Lipoproteins and Their Receptors in the Central Nervous System. Journal of Biological Chemistry 262(29):14352-14360.
  192. Rodriguez, G. A., et al. 2013 Young APOE4 targeted replacement mice exhibit poor spatial learning and memory, with reduced dendritic spine density in the medial entorhinal cortex. Learning & Memory 20(5):256-266.
  193. Rodriguez, Gustavo A., et al. 2014 Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition. Journal of Neuroinflammation 11(111):1-13.
  194. Rubinsztein, D. C., C. F. Bento, and V. Deretic 2015 Therapeutic targeting of autophagy in neurodegenerative and infectious diseases. J Exp Med 212(7):979-90.
  195. Ruiz, Jose, et al. 2005 The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. Journal of Lipid Research 46(8):1721-1731.
  196. Sagare, Abhay, et al. 2007 Clearance of amyloid-β by circulating lipoprotein receptors. Nature Medicine 13(9):1029-1031.
  197. Savonenko, A., et al. 2005 Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 18(3):602-17.
  198. Scahill, R. I., et al. 2002 Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A 99(7):4703-7.
  199. Schramm, Gerrit, and Rebecca Ramey 2005 siRNA design including secondary structure target site prediction. Nature Methods 2(8):632-632.
  200. Selkoe, Dennis J. 1999 Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399(6738):A23-A31.

200 of 245 shown

Cited by

Sorted by citations

Authors
Ferguson, C.
ORCID
Ferguson, Chantal
Venue
University of Massachusetts Medical School
Publisher
University of Massachusetts Medical School
Published
2021
DOI
10.13028/qk23-zg81
References
0

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review